Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sbr

Phase 3

Sbr is one of 54 therapeutic programs targeting HIV-1 infection. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

53

Competitors

Pipeline

Status by Indication[2][1]

Indication

HIV-1 InfectionRecruiting

HIV-1 InfectionPhase 3

Recruiting

Competition

Competitive Landscape

66 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

Tybost

Taxol

Cabenuva

Niacor

Epidiolex

Jazz Pharmaceuticals

Istodax

Renvela

Ziagen

Crestor

Bayer Aspirin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2033

Phase 3Recruiting

HIV-1 Infection

NCT07683000

Clinical

Trials by Indication[1]

HIV-1 infection1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Recruiting· Gilead logo

Gilead·Phase 3·NCT07683000·590 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sbr. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Sbr. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Gilead

Related News